厄贝沙坦联合美托洛尔治疗慢性充血性心衰的疗效观察  

作　　者：陈端[1] 侯维宁[1] 张立建[1] 钟世勤[1] 钟惠娟[1] 

机构地区：[1]广东广州医学院荔湾医院心内科,510175

出　　处：《中国社区医师（医学专业）》2011年第20期35-36,共2页

摘　　要：目的:探讨厄贝沙坦联合美托洛尔治疗慢性充血性心衰的临床疗效。方法:120例慢性充血性心衰患者作为研究对象,被随机分为实验组和对照组,两组均给予常规治疗,对照组加用美托洛尔,起始剂量6.25mg/日,维持剂量25mg/日;实验组在对照组基础上给予厄贝沙坦,150mg/日。两组疗程均为3个月。结果:①实验组总有效率显著优于对照组(X2=5.841,P<0.05)。②实验组在LVEF(t=3.816,P<0.05)、LVEDD(t=3.547,P<0.05)和LVESD(t=3.241,P<0.05)等方面显著优于对照组。结论:厄贝沙坦和美托洛尔联合使用,可显著提高治疗效果,改善患者生活质量,值得临床应用推广。Objective： To explore the clinical effect of lrbesartan combined with metoprolol used for chronic congestive heart failure. Methods： 120 cases of patients as studied object were randomly divided into experimental group and control group. Both groups were given routine therapy, and control group were added to metoprolol, starting dose ：6. 25 mg/d, maintenance dose ： 25mg/ d. Experimental group were added to lrbesartan（150mg/d） on base of control group. Period of treatment of two groups were 3 months. Results： （1）The total effective rate in experimental group were significantly better than that in control group（X2 =5. 841 ,P 〈0. 05）. （2）LVEF（t = 3. 816,P 〈0. 05） LVEDD（t = 3. 547,P 〈 0. 05） and LVESD in experimental group were significantly better than that in control group （ t = 3. 816, P 〈0. 05;t =3. 547,P〈0. 05;t =3.241,P 〈 0.05 ）. Conclusion： Irbesartan combined with metoprolol can enhance clinical effect and improve life quality significantly, so it is a desirable therapy method in clinical work.

关 键 词：厄贝沙坦 美托洛尔 慢性充血性心衰 

分 类 号：R541.61[医药卫生—心血管疾病]